Notice of Meetings, 46013-46014 [2019-18928]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 170 / Tuesday, September 3, 2019 / Notices
0077, Quality Assurance Requirements,
in all correspondence related to this
collection. Comments received generally
will be posted without change to https://
www.regulations.gov, including any
personal and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check www.regulations.gov,
approximately two-to-three days after
submission to verify posting (except
allow 30 days for posting of comments
submitted by mail).
FOR FURTHER INFORMATION CONTACT: Ms.
Marilyn Chambers, Procurement
Analyst, at 202–285–7380 or email
marilyn.chambers@gsa.gov.
SUPPLEMENTARY INFORMATION:
A. OMB control number, Title, and any
Associated Form(s)
9000–0077, Quality Assurance
Requirements.
B. Needs and Uses
Supplies and services acquired under
Government contracts must conform to
the contract’s quality and quantity
requirements. FAR Part 46 prescribes
inspection, acceptance, warranty, and
other measures associated with quality
requirements. Standard inspection
clauses require the contractor to provide
and maintain an inspection system that
is acceptable to the Government; give
the Government the right to make
inspections and test while work is in
process; and require the contractor to
keep complete, and make available to
the Government, records of its
inspection work. FAR clause 52.246–15,
Certificate of Conformance, is not an
inspection clause, but a requirement for
the contractor to certify that supplies or
services furnished are of the quality
specified and conform in all respects
with the contract requirements.
C. Annual Burden
required to provide the records is
estimated as follows:
Respondents: 1,590.
Total Annual Responses: 1,590.
Total Burden hours: 1,590.
2. Certificate of Conformance
FAR clause 52.246–15 is used in
solicitations and contracts for supplies
or services at the discretion of the
contracting officer when it is in the
Government’s interest, small losses
would be incurred in the event of a
defect; or because of the contractor’s
reputation or past performance, it is
likely that the supplies or services
furnished will be acceptable and any
defective work would be replaced,
corrected, or repaired without contest.
The clause requires the contractor to
submit a prescribed certificate. The time
required to submit the certificate is
estimated as follows:
Respondents: 639.
Total Annual Responses: 639.
Total Burden hours: 320.
D. Public Comment
A 60-day notice published in the
Federal Register at 84 FR 28813 on June
20, 2019. No comments were received.
Obtaining Copies: Requesters may
obtain a copy of the information
collection documents from the General
Services Administration, Regulatory
Secretariat Division (MVCB), 1800 F
Street NW, Washington, DC 20405,
telephone 202–501–4755. Please cite
OMB Control No. 9000–0077, Quality
Assurance Requirements, in all
correspondence.
Dated: August 27, 2019.
Janet Fry,
Director, Federal Acquisition Policy, Office
of Governmentwide Acquisition Policy, Office
of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2019–18906 Filed 8–30–19; 8:45 am]
BILLING CODE 6820–EP–P
khammond on DSKBBV9HB2PROD with NOTICES
1. Inspection Clauses
The FAR inspection clauses are used
for quality assurance depending on the
type of contract and the type of product
or service being provided. The
corresponding quality/inspection
systems the contractors are required to
implement have requirements for record
keeping and in some cases documenting
the quality or inspection system. These
clauses do not require the transmittal or
sending of documentation to the
Government. Instead, the Government
may review these records to confirm the
contract quality requirements are being
met. Definitive information was not
available on how often the Government
requests to see these records. The time
VerDate Sep<11>2014
16:24 Aug 30, 2019
Jkt 247001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Notice of Meetings
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Notice of Five AHRQ
subcommittee meetings.
AGENCY:
The subcommittees listed
below are part of AHRQ’s Health
Services Research Initial Review Group
Committee. Grant applications are to be
reviewed and discussed at these
SUMMARY:
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
46013
meetings. Each subcommittee meeting
will commence in open session before
closing to the public for the duration of
the meeting.
DATES: See SUPPLEMENTARY INFORMATION
for meeting dates of the individual
subcommittees.
Bethesda North Marriott
Hotel & Conference Center, 5701
Marinelli Road, Bethesda, Maryland
20852.
ADDRESSES:
(to
obtain a roster of members, agenda or
minutes of the non-confidential portions
of the meetings.) Heather Phelps, Acting
Committee Management Officer, Office
of Extramural Research Education and
Priority Populations, Agency for
Healthcare Research and Quality
(AHRQ), 5600 Fishers Lane, Rockville,
Maryland 20857, Telephone (301) 427–
1128.
SUPPLEMENTARY INFORMATION: In
accordance with section 10 (a)(2) of the
Federal Advisory Committee Act (5
U.S.C. App. 2), AHRQ announces
meetings of the above-listed scientific
peer review groups, which are
subcommittees of AHRQ’s Health
Services Research Initial Review Group
Committees. Each subcommittee
meeting will commence in open session
before closing to the public for the
duration of the meeting. The
subcommittee meetings will be closed to
the public in accordance with the
provisions set forth in 5 U.S.C. App. 2
section 10(d), 5 U.S.C. 552b(c)(4), and 5
U.S.C. 552b(c)(6). The grant applications
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
The meeting dates for the
subcommittees are:
1. Healthcare Effectiveness and
Outcomes Research (HEOR)
Date: October 9th, 2019 (Open from
8:00 a.m. to 8:30 a.m. on October
9th and closed for remainder of the
meeting)
2. Health System and Value Research
(HSVR)
Date: October 16th, 2019 (Open from
8:00 a.m. to 8:30 a.m. on October
16th and closed for remainder of
the meeting)
3. Health Care Research and Training
(HCRT)
Date: October 17–18th, 2019 (Open
from 8:00 a.m. to 8:30 a.m. on
October 17th and closed for
remainder of the meeting)
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\03SEN1.SGM
03SEN1
46014
Federal Register / Vol. 84, No. 170 / Tuesday, September 3, 2019 / Notices
4. Healthcare Safety and Quality
Improvement Research (HSQR)
Date: October 10–11th, 2019 (Open
from 7:30 a.m. to 8:00 a.m. on
October 10th and closed for
remainder of the meeting)
5. Healthcare Information Technology
Research (HITR)
Date: October 24th, 2019 (Open from
8:00 a.m. to 8:30 a.m. on October
24th and closed for remainder of
the meeting)
Agenda items for these meetings are
subject to change as priorities dictate.
Virginia L. Mackay-Smith,
Associate Director, AHRQ.
[FR Doc. 2019–18928 Filed 8–30–19; 8:45 am]
BILLING CODE 4160–90–P
• Mail: Division of Healthcare Quality
Promotion, National Center for
Emerging and Zoonotic Infectious
Diseases, Centers for Disease Control
and Prevention, Attn: Docket No. CDC–
2019–0077, HICPAC Secretariat, 1600
Clifton Rd. NE, Mailstop A07, Atlanta,
Georgia 30329.
Instructions: Submissions via https://
regulations.gov are preferred. All
submissions received must include the
agency name and Docket Number. All
relevant comments received will be
posted without change to https://
regulations.gov, including any personal
information provided. For access to the
docket to read background documents
or comments received, go to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2019–0077]
Draft Guideline for Prevention and
Control of Infections in Neonatal
Intensive Care Unit Patients: Draft
Recommendations for the Prevention
and Control of Staphylococcus aureus
in Neonatal Intensive Care Unit
Patients
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), in the
Department of Health and Human
Services (HHS), announces the opening
of a docket to obtain comment on the
Draft Guideline for Prevention and
Control of Infections in Neonatal
Intensive Care Unit Patients: Draft
Recommendations for the Prevention
and Control of Staphylococcus aureus in
Neonatal Intensive Care Unit Patients
(‘‘Draft Guideline’’). The Draft Guideline
provides new, evidence-based
recommendations specific to the
prevention and control of
Staphylococcus aureus (S. aureus),
including methicillin-resistant S. aureus
(MRSA) and methicillin-sensitive S.
aureus (MSSA), in neonatal intensive
care unit (NICU) patients.
DATES: Written comments must be
received on or before November 4, 2019.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2019–
0077, by any of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
khammond on DSKBBV9HB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:24 Aug 30, 2019
Jkt 247001
Kendra Cox, Division of Healthcare
Quality Promotion, National Center for
Emerging and Zoonotic Infectious
Diseases, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop A–07, Atlanta, Georgia 30329;
Telephone: (404) 639–4000.
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data.
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign. CDC will carefully
consider all comments submitted in
preparation of the final Guideline for
Prevention and Control of Infections in
Neonatal Intensive Care Unit Patients
and may revise the final document as
appropriate.
The Draft Guideline, located in the
‘‘Supporting & Related Material’’ tab of
the docket, provides new, evidencebased recommendations specific to the
Frm 00071
Dated: August 28, 2019.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2019–18907 Filed 8–30–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–3240]
List of Bulk Drug Substances for
Which There is a Clinical Need Under
Section 503B of the Federal Food,
Drug, and Cosmetic Act
AGENCY:
Background
PO 00000
prevention and control of S. aureus,
including MRSA and MSSA, in NICU
patients, including active surveillance
testing and decolonization.
The Draft Guideline is intended for
use by infection prevention staff,
healthcare epidemiologists, healthcare
administrators, nurses, neonatologists,
other healthcare providers, and persons
responsible for developing,
implementing, and evaluating infection
prevention and control programs for
NICUs. The guideline can also serve as
a resource for societies or organizations
to develop more detailed
implementation guidance for the
prevention of infection in NICU
patients.
The Healthcare Infection Control
Practices Advisory Committee (HICPAC)
worked with national partners,
academicians, public health
professionals, healthcare providers, and
other partners to develop this Draft
Guideline. HICPAC includes
representatives from public health,
infectious diseases, regulatory and other
federal agencies, professional societies,
and other stakeholders.
The draft recommendations in this
Draft Guideline are informed by a
systematic review of the best available
literature through February 2017 and of
relevant references published since
February 2017 suggested by subject
matter experts. The Appendix, located
in the ‘‘Supporting & Related Material’’
tab of the docket, contains search
strategies, Evidence Tables containing
study-level data examined, and GRADE
Tables which aggregate the overall
strength and direction of the evidence.
This Draft Guideline will not be a
federal rule or regulation.
Fmt 4703
Sfmt 4703
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
SUMMARY:
E:\FR\FM\03SEN1.SGM
03SEN1
]]>Agencies
[Federal Register Volume 84, Number 170 (Tuesday, September 3, 2019)]
[Notices]
[Pages 46013-46014]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18928]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Notice of Meetings
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Notice of Five AHRQ subcommittee meetings.
-----------------------------------------------------------------------
SUMMARY: The subcommittees listed below are part of AHRQ's Health
Services Research Initial Review Group Committee. Grant applications
are to be reviewed and discussed at these meetings. Each subcommittee
meeting will commence in open session before closing to the public for
the duration of the meeting.
DATES: See SUPPLEMENTARY INFORMATION for meeting dates of the
individual subcommittees.
ADDRESSES: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, Maryland 20852.
FOR FURTHER INFORMATION CONTACT: (to obtain a roster of members, agenda
or minutes of the non-confidential portions of the meetings.) Heather
Phelps, Acting Committee Management Officer, Office of Extramural
Research Education and Priority Populations, Agency for Healthcare
Research and Quality (AHRQ), 5600 Fishers Lane, Rockville, Maryland
20857, Telephone (301) 427-1128.
SUPPLEMENTARY INFORMATION: In accordance with section 10 (a)(2) of the
Federal Advisory Committee Act (5 U.S.C. App. 2), AHRQ announces
meetings of the above-listed scientific peer review groups, which are
subcommittees of AHRQ's Health Services Research Initial Review Group
Committees. Each subcommittee meeting will commence in open session
before closing to the public for the duration of the meeting. The
subcommittee meetings will be closed to the public in accordance with
the provisions set forth in 5 U.S.C. App. 2 section 10(d), 5 U.S.C.
552b(c)(4), and 5 U.S.C. 552b(c)(6). The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
The meeting dates for the subcommittees are:
1. Healthcare Effectiveness and Outcomes Research (HEOR)
Date: October 9th, 2019 (Open from 8:00 a.m. to 8:30 a.m. on
October 9th and closed for remainder of the meeting)
2. Health System and Value Research (HSVR)
Date: October 16th, 2019 (Open from 8:00 a.m. to 8:30 a.m. on
October 16th and closed for remainder of the meeting)
3. Health Care Research and Training (HCRT)
Date: October 17-18th, 2019 (Open from 8:00 a.m. to 8:30 a.m. on
October 17th and closed for remainder of the meeting)
[[Page 46014]]
4. Healthcare Safety and Quality Improvement Research (HSQR)
Date: October 10-11th, 2019 (Open from 7:30 a.m. to 8:00 a.m. on
October 10th and closed for remainder of the meeting)
5. Healthcare Information Technology Research (HITR)
Date: October 24th, 2019 (Open from 8:00 a.m. to 8:30 a.m. on
October 24th and closed for remainder of the meeting)
Agenda items for these meetings are subject to change as priorities
dictate.
Virginia L. Mackay-Smith,
Associate Director, AHRQ.
[FR Doc. 2019-18928 Filed 8-30-19; 8:45 am]
BILLING CODE 4160-90-P
